USPTO serial 79355609
SOM BIOTECH
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 4, 2024
- Examiner
- HARMON, RAYMOND E
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with SOM BIOTECH?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the prevention of diseases of the nervous system; pharmaceutical preparations for treating metabolic disorders; chemical preparations for pharmaceutical purposes for the treatment of diseases of the nervous system, metabolic disorders, malignant tumors, for activating cellular function, for cardiovascular and cerebrovascular diseases, for the treatment of Parkinson's disease, for the prevention of diseases of the respiratory system, for gastro-intestinal disorders, for the treatment of infectious diseases, for movement disorders, for oncologic diseases, for immune system diseases, for skeletal muscular diseases, for hormone disorders, for skin diseases, for ophthalmologic disease, for gynecological diseases, for hematological diseases and for pediatric diseases; pharmaceutical agents affecting metabolism; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for activating cellular function; medicines for the treatment of cardiovascular and cerebrovascular diseases; pharmaceutical preparations for the treatment of parkinson's disease; pharmaceutical preparations for the prevention of diseases of the respiratory system; pharmaceutical preparations for the treatment of rare diseases being hereditary movement disorders such as Huntington disease, Tourette disease, tardive dyskinesia, hereditary muscular dystrophies, hereditary metabolic disorders, hereditary neurological diseases, amyloidosis, rare neurodegenerative diseases, myotonic dystrophy, spinal muscular atrophy, idiopathic pulmonary fibrosis, multiple sclerosis, neurofibromatosis, Acute Flaccid Myelitis, Devic's syndrome, rare cancers, neuropathic pain, ELA and diabetes; pharmaceuticals, for use in the field of treatment of hereditary diseases being Huntington's Disease, Phenylketonuria, Tay Sachs, Duchenne Muscular Dystrophy, Dystrophinopathies, GM2 gangliosidoses, Niemann Pick Disease, hereditary amyloidosis, hereditary Parkinson's Disease, adrenoleukodystrophy, Dravet syndrome, Batten disease, Fragile X syndrome, Friedrich Ataxia, Lennox Gastaut, Gaucher disease, cystic fibrosis, acute myeloid leukemia, sickle cell disease; pharmaceutical preparations for the treatment of gastro-intestinal disorders; pharmaceutical products for the treatment of infectious diseases; pharmaceuticals, for use in treatment of movement disorders; pharmaceutical preparations for use in oncology; pharmaceuticals for the treatment of immune system disease; pharmaceuticals, for use in the treatment of skeletal muscular diseases; pharmaceuticals, for use in the treatment of hormone disorders; pharmaceuticals, for use in the treatment of skin diseases; pharmaceutical preparations for use in ophthalmology; pharmaceuticals, for use in the treatment of gynaecological diseases; pharmaceuticals, for use in the treatment of haematological diseases; pharmaceuticals, for use in the treatment of paediatric diseases; reagents for use in medical genetic testing; clinical medical reagents; drug delivery agents consisting of compounds that modulate delivery of a wide range of pharmaceuticals; pharmaceutical preparations, namely, drug detoxifying agents; central nervous system stimulants; respiratory stimulants; cardiovascular drugs used in treating congestive heart failure (CHF); preparations for detecting genetic predispositions for medical purposes; cells for medical use; tumor suppressing agents; pharmaceutical preparations for treatment of tumors, namely, tumor antigens; biopharmaceuticals for the treatment of cancer | ACTIVE | — |
| 042 | Clinical research in the field of development of drugs discovered through artificial intelligence technology; biological research; chemical technological research in the field of development of drugs discovered through artificial intelligence technology; biomedical research services; research services in the fields of computation chemistry; medical and pharmacological research services in the field of drug discovery and development through artificial intelligence technology; research and development of vaccines and medicines; research and development in the field of microorganisms and cells; stem cell research services; research in the field of artificial intelligence technology; development of pharmaceutical preparations and medicines; implementation of preclinical trials, namely, conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of oncology, neurology, metabolic diseases, respiratory diseases, cardiovascular diseases, ophthalmologic diseases, gastro-intestinal diseases, dermatological diseases, musculoskeletal diseases, gynaecological diseases, paediatric diseases, infectious diseases, movement disorders, hormone disorders, immune system disorders, neurodegenerative diseases; clinical trials, namely, conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of oncology, neurology, metabolic diseases, respiratory diseases, cardiovascular diseases, ophthalmologic diseases, gastro-intestinal diseases, dermatological diseases, musculoskeletal diseases, gynaecological diseases, paediatric diseases, infectious diseases, movement disorders, hormone disorders, immune system disorders, neurodegenerative diseases; providing scientific information about the results of clinical trials for pharmaceutical products; consultancy pertaining to pharmacology; consultancy relating to research in the field of pharmacogenetics; consultancy relating to pharmaceutical research and development; chemistry consultation; providing information on the subject of scientific research in the field of biochemistry and biotechnology; laboratory analysis in the field of chemistry; design and development of medical technology; information technology (IT) consulting services for the pharmaceutical and healthcare industries; design and development of computer software for use with medical technology; design and development in relation to artificial intelligence technology; drug repositioning research; drug combination research | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SOM INNOVATION BIOTECH, S.A.
- Other trademarks owned by SOM INNOVATION BIOTECH, S.A.
- Other trademarks owned by SOM INNOVATION BIOTECH, S.A.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named SOM BIOTECH
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 7, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 16, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 15, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 4, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 4, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jun 4, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 7, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Apr 17, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 17, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Mar 19, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 19, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 28, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 28, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 14, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 14, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 14, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Feb 14, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 14, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 14, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 14, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 14, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 2, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 1, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 1, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 10, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 10, 2024 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jan 10, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 10, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 10, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jan 10, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 28, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 5, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 5, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 30, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 29, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 26, 2023 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| May 17, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 16, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 5, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 2, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 28, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 25, 2022 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Nov 17, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |